Mira Pharmaceuticals shares are trading higher after the company said it has advanced new preclinical studies using Ketamir-2 towards clinical development.
Portfolio Pulse from Benzinga Newsdesk
Mira Pharmaceuticals shares are trading higher after the company announced advancements in preclinical studies using Ketamir-2 towards clinical development.
May 20, 2024 | 2:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mira Pharmaceuticals shares are trading higher following the announcement of advancements in preclinical studies using Ketamir-2 towards clinical development.
The announcement of advancements in preclinical studies is a positive development for Mira Pharmaceuticals, indicating progress in their drug development pipeline. This news is likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100